Enterococcus faecalis Infective Endocarditis: Is It Time to Abandon Aminoglycosides?

dc.contributor.author	Munita, José
dc.contributor.author	Arias, Cesar A.
dc.contributor.author	Murray, Barbara E.
dc.date.accessioned	2021-10-13T16:44:48Z
dc.date.available	2021-10-13T16:44:48Z
dc.date.issued	2013
dc.description.abstract	Since the first description of enterococcal infective endocarditis (IE) in 1899 and the subsequent availability of antibiotics for the treatment of this life-threatening infection, clinicians have faced important challenges in the management of this disease Enterococci exhibit intrinsic antibiotic resistance (eg, to cephalosporins , clindamycin), are less susceptible to various antibiotics (eg, β-lactams) that are active against streptococci and staphylococci, and are often tolerant to compounds (penicillin) that normally have a bactericidal effect against other susceptible bacteria.The lack of efficacy of penicillin for many cases of enterococcal IE sparked interest in possible alternative therapies.	es
dc.identifier.citation	Clinical Infectious Diseases, 2013, 56(9):1269–72	es
dc.identifier.uri	http://dx.doi.org/10.1093/cid/cit050	es
dc.identifier.uri	http://hdl.handle.net/11447/4817
dc.language.iso	en	es
dc.subject	Enterococcus faecalis	es
dc.subject	High-level resistance	es
dc.subject	Infective endocarditis	es
dc.subject	Aminoglycosides	es
dc.title	Enterococcus faecalis Infective Endocarditis: Is It Time to Abandon Aminoglycosides?	es
dc.type	Article	es

Files

Now showing 1 - 1 of 1

Name:: Enterococcus faecalis Infective Endocarditis - Is It Time to Abandon Aminoglycosides.pdf
Size:: 113.9 KB
Format:: Adobe Portable Document Format
Description:: Texto completo restringido

Now showing 1 - 1 of 1